Impedimed Limited · ASX:IPD
Impedimed — Q3 FY25 Earnings Presentation
17 slides from Impedimed's earnings presentation, Apr 30, 2025
Slide 1: ASX cover letter: Investor Presentation
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 30 April 2025 For personal use only Companies Announcements Office Australian Securities Exchange Investor Presentation ImpediMed Limited (ASX:IPD) releases the attached presentatio
Slide 2: Q3 FY25 Results
For personal use only Impedimed Limited Q3 FY25 Results April 2025 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2025 ImpediMed Limited. 1
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 4: Agenda
Agenda For personal use only 1 Strategy Recap 2 Q3 Key Highlights 3 Business Overview 4 Financial Performance 5 Q4 FY25 Outlook Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2025 ImpediMed Limited. 3
Slide 5: Immediate strategy
Immediate strategy For personal use only Execute to breakeven with a focus of sales, marketing and clinical execution in BCRL 12-Month Priorities Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class custome
Slide 6: Key Q3 highlights
Key Q3 highlights Financial For personal use only • Record revenue $3.4m. • Record cash receipts $4.1m. • Quarterly operating cash outflow ($3.5m). • US$15m growth capital facility established, with US$10m Tranche 1 drawn in the quarter. • Cash balance $27.9m, equating to 8.1 quarters of operating c
Slide 7: Business Overview - Sales
Business Overview - Sales Continued focus on accelerating BCRL For personal use only • Solid foundation set - ARR business model, 1,000+ devices deployed, leading US healthcare customers, NCCN & NAPBC guideline inclusions. • Current reimbursement levels considered sufficient to support sales needed
Slide 8: Business Overview – Focus on sales conversion
Business Overview – Focus on sales conversion For personal use only Lead generation was an initial area of focus • Record number of leads generated in the quarter resulting from the following initiatives: • Improvement in field force productivity metrics and implementation of new systems such as Acu
Slide 9: Business Overview - Other
Business Overview - Other US tariffs For personal use only • After conducting a preliminary assessment, the Company does not expect any material impact. • The vast majority of the value in a standard 3-year contract is derived from the various software applications not subject to tariffs. • ImpediMe
Slide 10: Cash Flow
Cash Flow For personal use only Summarized Cash Flow FY25 In thousands Q1 Q2 Q3 AUD Actual Actual Actual Record quarterly cash receipts of $4.1m. Receipts from customers 2,718 3,419 4,059 • Q3 operating cash outflow of $3.5m, in line with forecast. Research & development (88) (78) (57) Product manuf
Slide 11: Revenue and Cash Receipts
Revenue and Cash Receipts For personal use only Revenue Quarterly Cash Receipts A$ millions A$ millions • Q3 FY25 revenue up 2% vs Q2 FY25. • Record quarterly cash receipts of $4.1m. • Q3 North America revenue up 5% vs Q2 FY25. • Q3 operating cash outflow of $3.5m in line with budget. • 28% growth v
Slide 12: ARR and TCV
ARR and TCV For personal use only SOZO Annual Recurring Revenue1 SOZO Core Business Quarterly Total Contract Value2 A$ millions A$ millions • ARR up 27% vs Q3 FY24; up 10% vs prior quarter. • Price of renewed contracts increased 19% on average. • ARR continues to grow as quarterly TCV gain • Signifi
Slide 13: Sales
Sales For personal use only Global Installed Base ROW Installed Base Patient Tests (000s) Units U.S. Installed base 21% 3-year CAGR1 • 36 SOZO Units Sold vs 49 Q2FY25 • 72,000 Patient Tests in Q3 FY25 • US units sales increase by 10% to 22 units from 20 in Q2FY25 • Up 3% versus Q2 FY25 • Reduction w
Slide 14: Q3 FY25 vs Outlook
Q3 FY25 vs Outlook For personal use only q Continued to initiate Lymphoedema awareness activities to generate leads q Measured investment to accelerate sales strategy q Continued focus on private payor coverage q Drive improvement in sales metrics q Optimise contract renewal outcomes q Continued foc
Slide 15: Outlook for Q4 FY25
Outlook for Q4 FY25 For personal use only q Significant increase in US sales expected in Q4 and the balance of the 2025 calendar year: q Continue to initiate Lymphoedema awareness activities to generate leads. q Further measured investment to accelerate sales strategy. q Drive improvement in sales m
Slide 16: The Value Proposition
The Value Proposition Multiple Regulatory For personal use only Clearances Lymphoedema Heart Failure Reimbursement Renal Failure 75% of US Body Comp Successful Insured Lives covered Global RCT Lymphoedema Critical mass prevention coverage in 25 US States Guideline and Initial TAM Standard $600M Incl
Slide 17: For personal use only
impedimed’ Ajuo asn jeuosiad 104 16